NSE, a potential biomarker, is closely connected to diabetic peripheral neuropathy

Diabetes Care

Volumn 36, Issue 11, 2013, Pages 3405-3410

  Li, Jianbo ^a   Zhang, Hongman ^a   Xie, Min ^a   Yan, Lingfei ^a   Chen, Jiawei ^a   Wang, Hongxing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NEURON SPECIFIC ENOLASE; STATINE DERIVATIVE; SULFONYLUREA DERIVATIVE; BIOLOGICAL MARKER; ENOLASE;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG WITHDRAWAL; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; ELECTROMYOGRAPHY; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; STAGING; BLOOD; COMPLICATION; DIABETIC NEUROPATHIES; MIDDLE AGED;

ADULT; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE;

EID: 84891867745     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0590     Document Type: Article

References (29)

1. Boulton AJ. Diabetic neuropathy: classification, measurement and treatment. Curr Opin Endocrinol Diabetes Obes 2007;14: 141-145
2. Kaiser E, Kuzmits R, Pregant P, Burghuber O, Worofka W. Clinical biochemistry of neuron specific enolase. Clin Chim Acta 1989;183:13-31
3. Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci 1987;10:269-295
4. Marieb EN, Hoehn K. Human Anatomy & Physiology. 7th ed. London, UK, Pearson, 2007, p. 388-602
5. Mielke R, Schröder R, Fink GR, Kessler J, Herholz K, Heiss WD. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol 1996;91:174-179
6. Fernyhough P, Roy Chowdhury SK, Schmidt RE. Mitochondrial stress and the pathogenesis of diabetic neuropathy. Expert Rev Endocrinol Metab 2010;5:39-49
7. Dyck PJ, Zimmerman BR, Vilen TH, et al. Nerve glucose, fructose, sorbitol, myoinositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med 1988;319:542-548
8. Sandhu HS, Butt AN, Powrie J, Swaminathan R. Measurement of circulating neuron-specific enolasemRNA in diabetes mellitus. Ann N Y Acad Sci 2008;1137:258-263
9. Yang W, Lu J, Weng J, et al.; China National Diabetes and Metabolic Disorders StudyGroup. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-1101
10. World Health Organization. Diabetes Mellitus: Report of aWHO Study Group. Geneva, World Health Org., 2006
11. Dyck PJ, ShermanWR, Hallcher LM, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980;8: 590-596
12. Yarnitsky D, Sprecher E. Thermal testing: normative data and repeatability for various test algorithms. J Neurol Sci 1994; 125:39-45
13. Shukla G, Bhatia M, Behari M. Quantitative thermal sensory testingdvalue of testing for both cold and warm sensation detection in evaluation of small fiber neuropathy. Clin Neurol Neurosurg 2005;107: 486-490
14. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988;11:21-32
15. Jianbo L, Yuche C,Ming S, et al. Association of homocysteine with peripheral neuropathy inChinese patients with type 2 diabetes. Diabetes Res Clin Pract 2011;93:38-42
16. Feldman EL, Stevens MJ, Thomas PK, BrownMB,CanalN,GreeneDA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17:1281-1289
17. Ewing DJ. Analysis of heart rate variability and other non-invasive tests with special reference to diabetes mellitus. In Autonomic Failure. Vol 16, 3rd ed. Bannister R, Mathias CJ, Eds. Oxford, Oxford University Press, 1992, p. 312-333
18. Summary of revisions for the 2006 Clinical Practice Recommendations. Diabetes Care 2006;29(Suppl. 1):S3
19. Selakovic V, Raicevic R, Radenovic L. The increase of neuron-specific enolase in cerebrospinal fluid and plasma as a marker of neuronal damage in patients with acute brain infarction. J Clin Neurosci 2005;12: 542-547
20. Wunderlich MT, Ebert AD, Kratz T, Goertler M, Jost S, Herrmann M. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 1999;30: 1190-1195
21. Clegg N, Ferguson C, True LD, et al. Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 2003;55:55-64
22. Kasprzak A, Zabel M, Biczysko W. Selected markers (chromogranin A, neuronspecific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours. Pol J Pathol 2007;58:23-33
23. Nemeth J, Galian A, Mikol J, Cochand-Priollet B, Wassef M, Lavergne A. Neuronspecific enolase and malignant lymphomas (23 cases). Virchows Arch A Pathol Anat Histopathol 1987;412:89-93
24. Preece P, CairnsNJ. QuantifyingmRNA in postmortem human brain: influence of gender, age at death, postmorteminterval, brain pH, agonal state and inter-lobe mRNA variance. Brain Res Mol Brain Res 2003;118:60-71
25. Xiaofang Y, Yue Z, Xialian X, Zhibin Y. Serum tumour markers in patients with chronic kidney disease. Scand J Clin Lab Invest 2007;67:661-667
26. Pandey A, Saxena K, Verma M, Bharosay A. Correlative study between neuronspecific enolase and blood sugar level in ischemic stroke patients. J Neurosci Rural Pract 2011;2:50-54
27. Price TO, Eranki V, Banks WA, Ercal N, Shah GN. Topiramate treatment protects bloodbrain barrier pericytes from hyperglycemiainduced oxidative damage in diabetic mice. Endocrinology 2012;153:362-372
28. Sensenbrenner M, Lucas M, Deloulme JC. Expression of two neuronal markers, growth-associated protein 43 and neuronspecific enolase, in rat glial cells. J MolMed (Berl) 1997;75:653-663
29. van Dijk HW, Verbraak FD, Kok PH, et al. Early neurodegeneration in the retina of type 2 diabetic patients. Invest Ophthalmol Vis Sci 2012;53:2715-2719